Carl Zeiss Meditec records positive first quarter

Revenue up four per cent, Microsurgery and Surgical Ophthalmology are strong

(PresseBox) ( Jena, Germany, )
Irrespective of the difficult underlying global economic conditions, Carl Zeiss Meditec AG closed the first quarter of financial year 2012/2013 with solid earnings. The medical technology company's revenues were up by four per cent to EUR 219.0m compared to the same quarter of the previous year; profitability and earnings per share were also up.

In the first three months of the new financial year, the company recorded revenues of EUR 219.0m (previous year: EUR 210.3m) and EBIT of EUR 31.2m (previous year: EUR 28.3m). The EBIT margin improved from 13.4 per cent to 14.3 per cent; earnings per share increased compared to the same quarter of the previous year from EUR 0.21 to EUR 0.29. The strategic business units exhibited very different performance.

"Our positive overall growth is due, in particular, to the balanced and broad footing of our business," commented Dr. Ludwin Monz, Carl Zeiss Meditec AG's President and CEO. "In view of the reserved economic growth in many global markets, the investments we have made in Asia are really paying off now."

Revenue by business unit

The Microsurgery strategic business unit (SBU) continued to be profitable and displayed strong growth in the first quarter. Its revenues were up by 10.3 per cent.

In contrast, revenues in the Ophthalmic Systems SBU were down by 6.9 per cent with a positive contribution to earnings. As a result of a comprehensive change of models at the end of the year, revenues for Optical Coherence Tomography (OCT) decreased. At the same time, a higher level of competition was increasingly noticeable in some segments of this business unit.

Revenue in the Surgical Ophthalmology SBU grew by 21.2 per cent. In particular, a new product line for premium intraocular lenses contributed to the positive development.

Revenue by region

In the EMEA region (Europe, Middle East, Africa) revenues were up by 1.2 per cent with continued, highly non-uniform growth. Germany has continued to be the main sales driver and enjoyed positive growth; the Russian market also proved its continued strength, whereas the most of the other countries recorded reserved or negative growth.

Performance in the Americas region was weak during the quarter. Excellent growth rates in South America were counteracted by negative figures on the US market.

Once again, the APAC (Asia/Pacific) region recorded substantially double-digit growth of 14.1 per cent. China, Japan and Australia made particularly strong contributions to this growth.

In the words of Ludwin Monz, Carl Zeiss Meditec is, on the whole, positioned robustly enough to also deal well with a weaker global economy. "A slower pace of growth will also be reflected in our business over the longer term. However, as things stand today, we are sticking to our targets through to 2015."
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an